Cases / 2025-10-15-D-1255
completed2025-10-15D series

Nirogacestat

Desmoid-Tumor, fortgeschritten

Open official case page ↗
Brand
Ogsiveo
Manufacturer
SpringWorks Therapeutics Ireland Limited

G-BA action

final resolution

2026-04-02

Arzneimittel-​​​Richtlinie/Anlage XII: Nirogacestat (Desmoidtumor, fortgeschritten)

Evidence-checked summary

The G-BA found a hint of minor added benefit for Erwachsene mit fortschreitenden Desmoidtumoren, die eine systemische Behandlung erfordern. The G-BA issued a final resolution on 2026-04-02. The official page states that it took effect as follows: 02.04.2026. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.

This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.

Final benefit result

G-BA result by patient group

Open decision 7764 →

Patient group

Erwachsene mit fortschreitenden Desmoidtumoren, die eine systemische Behandlung erfordern

Hint of minor added benefit

Comparator

Open official result PDF ↗

Official case record

What happened, in source order

No inferred stages

Consultation record

Oral hearing and Wortprotokoll

1 hearing

2026-02-23

103 parsed turns

Oral hearing: Nirogacestat (Desmoid-Tumor, fortgeschritten)

Official Wortprotokoll · 14 pages

IQWiG comparison

Assessment record versus G-BA action

0 reference

IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.

No IQWiG assessment reference is present on the validated official case page. This is an explicit absence, not a broken graph link.

G-BA decisions

Distinct actions and documents

1 decision

2026-04-02

final resolution

Arzneimittel-​​​Richtlinie/Anlage XII: Nirogacestat (Desmoidtumor, fortgeschritten)

The G-BA found a hint of minor added benefit for Erwachsene mit fortschreitenden Desmoidtumoren, die eine systemische Behandlung erfordern. The G-BA issued a final resolution on 2026-04-02. The official page states that it took effect as follows: 02.04.2026. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.

3 official documents · 4 cited claims

Official sources

Case document package

8 source
Generic graph relations · 5